Bristol-Myers Takes Hit in Fourth Quarter, Plavix Continues to Drive Sales

The drug maker Bristol-Myers Squibb said higher taxes and the ongoing costs of restructuring hurt its fourth quarter results while sales of its medicines rose a slim 2 percent.
NJ